Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
December 06, 2024 12:01 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Rapport presents new data on the linear relationship between a seizure biomarker used in the company's RAP-219 POC trial and clinical seizures.
November 14, 2024 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule...
November 07, 2024 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing;...
November 04, 2024 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule...
September 05, 2024 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
August 29, 2024 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit

BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
August 08, 2024 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update

Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline
July 29, 2024 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

BOSTON and SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
June 12, 2024 16:01 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...